EGFR and COVID-19: Notably, hyperoside showed favorable predicted interactions with PI3K-Akt pathway-related targets (EGFR, PI3K, and Akt), while molecular dynamics simulations supported stable interactions with several COVID-19-related targets, including ACE2, Mpro, and RdRp.